Canariabio Inc.

This study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian, fallopian tube, or peritoneal cancer. About 88 newly diagnosed patients will receive either the drug combo or chemo alone before and after surgery. Th…

This study tests whether adding oregovomab to the standard drug niraparib can help control platinum-sensitive recurrent ovarian cancer. Ten adults whose cancer returned after initial chemotherapy will receive both drugs. The goal is to see if the combination shrinks tumors or kee…

This study tests a combination of drugs (oregovomab, bevacizumab, paclitaxel, carboplatin) in adults with a specific type of recurrent ovarian cancer that has returned after initial treatment. The goal is to see if the combo is safe and shrinks tumors. About 54 participants with …

This study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian cancer live longer without their cancer growing. About 615 newly diagnosed patients who had surgery to remove most of their cancer will receive either …